4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference, scheduled for February 16, 2022, at 2:00 p.m. PT. The event will take the form of a fireside chat, and a live audio webcast will be accessible through the company’s website, with a replay available for two weeks post-event. 4DMT focuses on targeted gene therapies, currently developing five clinical-stage products for conditions including Fabry disease, wet AMD, and cystic fibrosis.

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) --  4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11^th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16^th. Details of the fireside chat are as follows:

Event: 11^th Annual SVB Leerink Global Healthcare Conference

Date & Time: Wednesday, February 16, 2022 at 2:00 p.m. PT

Format: Fireside Chat

A live audio webcast of the fireside chat will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.

About 4DMT

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused on five clinical-stage products in three therapeutic areas: ophthalmology, cardiology (including Fabry disease) and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The five 4DMT product candidates in clinical development are: 4D-310 for Fabry disease, 4D-150 for wet AMD, 4D-125 for XLRP, 4D-110 for choroideremia and 4D-710 for cystic fibrosis.

Contacts:

Media:

Carolyne Zimmermann
Chief Business Officer
czimmermann@4dmt.com

Investors:

Mike Zanoni
VP, Investor Relations
mzanoni@4dmt.com

FAQ

When is the 11th Annual SVB Leerink Global Healthcare Conference for FDMT?

The conference will take place on February 16, 2022, at 2:00 p.m. PT.

What format will the presentation at the SVB Leerink Global Healthcare Conference be?

The presentation will be conducted as a fireside chat.

How can I access the live webcast for FDMT's presentation?

The live audio webcast can be accessed via the 'Investors & Media' section of 4D Molecular Therapeutics' website.

What are the main areas of focus for 4D Molecular Therapeutics?

4DMT is focused on gene therapies in ophthalmology, cardiology, and pulmonology.

What clinical products are currently being developed by FDMT?

FDMT is developing five products including 4D-310 for Fabry disease and 4D-150 for wet AMD.